Gastrointestinal Cancer | Topics

Sam Klempner, MD, Reviews ctDNA Role in Gastroesophageal Cancers
April 04, 2022

Sam Klempner, MD, spoke about utilizing ctDNA the treat nonmetastatic gastroesophageal cancers at 2022 IGCC.

FDA Accepts Futibatinib NDA for Priority Review in Cholangiocarcinoma
March 30, 2022

A new drug application for futibatinib has been accepted for priority review in patients with previously treated locally advanced or metastatic cholangiocarcinoma with FGFR2 gene rearrangements.

Yelena Y. Janjigian, MD, Reviews MSI as a Biomarker in for Localized Gastric Cancer
March 22, 2022

Yelena Y. Janjigian, MD, spoke about which biomarkers were most predictive for treatment of localized gastric cancer.

Yelena Y. Janjigian, MD, Considers Immunotherapy Treatment Options for Gastric Cancer
March 15, 2022

Yelena Y. Janjigian, MD, spoke about using immunotherapy across settings to treat localized gastric cancer.

The Emerging Value of ctDNA in Colon Cancer Adjuvant Therapy Decisions
March 10, 2022

In this month’s Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, reviews results of the CIRCULATE-Japan clinical trial that were presented at the 2022 Gastrointestinal Cancers Symposium.

Yelena Y. Janjigian, MD, Discusses Immunotherapy for Gastric Cancer
March 06, 2022

Yelena Y. Janjigian, MD, spoke about using immunotherapy to treat localized gastric cancer.

Phase 3 Trial of NUC-1031/Cisplatin Discontinued for Advanced Biliary Tract Cancer
March 05, 2022

NUC-1031 plus cisplatin was unlikely to reach a primary end point of improved overall survival in advanced biliary tract cancer, leading to the discontinuation of the phase 3 NuTide:121 trial.

177Lu-Dotatate Yields Clinically Relevant But Non-Significant OS Benefit for Midgut NETs
February 27, 2022

Patients with advanced midgut neuroendocrine tumors experienced a clinically relevant improvement in median overall survival when treated with 177Lu-Dotatate compared with the control of high-dose long-acting octreotide, although the difference was not significant.

First-Line Nivolumab Combos Yield Improved OS Vs Chemo Alone in Esophageal Cancer
February 22, 2022

The CheckMate 648 trial found that using a combination of nivolumab and chemotherapy or nivolumab plus ipilimumab vs chemotherapy alone improved survival in advanced esophageal squamous-cell carcinoma.

Leveraging Surgical Oncology to Treat Gastrointestinal Cancers
February 14, 2022

“The pendulum is moving fast towards giving chemotherapy prior to surgery, and the research is going on to continue that trend.”